ADVANCED HIGH-GRADE EPITHELIAL OVARIAN CANCER
Clinical trials for ADVANCED HIGH-GRADE EPITHELIAL OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HIGH-GRADE EPITHELIAL OVARIAN CANCER trials appear
Sign up with your email to follow new studies for ADVANCED HIGH-GRADE EPITHELIAL OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis phase 3 trial tests whether adding trastuzumab deruxtecan (T-DXd) to standard bevacizumab maintenance therapy can delay cancer progression better than bevacizumab alone in people with HER2-expressing advanced ovarian cancer. About 582 adults whose cancer has a specific prote…
Matched conditions: ADVANCED HIGH-GRADE EPITHELIAL OVARIAN CANCER
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug aimed at Hard-to-Treat ovarian cancer shows promise in trial
Disease control Recruiting nowThis study tests a drug called mirvetuximab soravtansine (MIRV) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy and has high levels of a protein called FRα. The drug delivers a cancer-killing agent directly to tumor ce…
Matched conditions: ADVANCED HIGH-GRADE EPITHELIAL OVARIAN CANCER
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC